Financials data is unavailable for this security.
View more
Year on year Zimmer Biomet Holdings Inc grew revenues 6.55% from 6.94bn to 7.39bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 342.52% net income growth from 231.40m to 1.02bn.
| Gross margin | 71.78% |
|---|---|
| Net profit margin | 14.28% |
| Operating margin | 16.47% |
| Return on assets | 5.05% |
|---|---|
| Return on equity | 8.71% |
| Return on investment | 5.82% |
More ▼
Cash flow in USDView more
In 2023, Zimmer Biomet Holdings Inc increased its cash reserves by 10.67%, or 40.10m. The company earned 1.58bn from its operations for a Cash Flow Margin of 21.39%. In addition the company used 778.90m on investing activities and also paid 763.50m in financing cash flows.
| Cash flow per share | 9.99 |
|---|---|
| Price/Cash flow per share | 10.46 |
| Book value per share | 62.00 |
|---|---|
| Tangible book value per share | -6.03 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.36 |
|---|---|
| Quick ratio | 0.6987 |
| Total debt/total equity | 0.5213 |
|---|---|
| Total debt/total capital | 0.3425 |
More ▼
Growth rates in USD
SmartText is unavailable
| Div yield(5 year avg) | 0.72% |
|---|---|
| Div growth rate (5 year) | 0.00% |
| Payout ratio (TTM) | 18.09% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 132.70 |
More ▼
